Skip to Content
Merck
All Photos(1)

Documents

30165

Sigma-Aldrich

Tirofiban

≥98.5% (HPLC)

Synonym(s):

(2S)-2-(Butylsulfonylamino)-3-{4-[4-(4-piperidyl)butoxy}phenyl propanoic acid, N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H36N2O5S
CAS Number:
144494-65-5
Molecular Weight:
440.60
Beilstein:
6182267
MDL number:
MFCD05237246
UNSPSC Code:
12352106
PubChem Substance ID:
329753339
NACRES:
NA.25

Quality Level

100

Assay

≥98.5% (HPLC)

form

powder

SMILES string

CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O

InChI

1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1

InChI key

COKMIXFXJJXBQG-NRFANRHFSA-N

Gene Information

human ... ITGA2B(3674) , ITGB3(3690)

Application


  • The efficacy and safety of continuous intravenous tirofiban for acute ischemic stroke patients treated by endovascular therapy: a meta-analysis.: This meta-analysis assesses the safety and efficacy of continuous intravenous tirofiban in patients undergoing endovascular therapy for acute ischemic stroke, showing promising results for improved outcomes (Wang et al., 2024).

  • Initial Experience with a New Self-Expanding Open-Cell Stent System with Antithrombotic Hydrophilic Polymer Coating (pEGASUS Stent) in the Treatment of Wide-Necked Intracranial Aneurysms.: This study reports on the initial use of a new stent system coated with tirofiban in treating intracranial aneurysms, demonstrating enhanced safety and efficacy (Boxberg et al., 2024).

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Volker Maus et al.
World neurosurgery, 111, e424-e433 (2017-12-27)
Acute dissecting aneurysms of the posterior circulation are a rare cause of subarachnoid hemorrhage. Established endovascular treatment options include parent artery occlusion and stent-assisted coiling, but appear to be associated with an increased risk of ischemic stroke. Vessel reconstruction with
Veysel Ozan Tanık et al.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 28(2), 115-123 (2018-11-19)
In this study, we aimed to determine the predictive value of the CHA2DS2VASc score for acute stent thrombosis in patients with an ST elevation myocardial infarction treated with a primary percutaneous coronary intervention (pPCI). This was a retrospective study conducted
K J McClellan et al.
Drugs, 56(6), 1067-1080 (1999-01-08)
Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. Adenosine diphosphate (ADP)-induced platelet aggregation returns to near-baseline levels within 4 to 8 hours
Jan H Cornel et al.
The American journal of cardiology, 115(10), 1325-1332 (2015-03-18)
We evaluated the interaction between protease-activated receptor-1 antagonist vorapaxar and concomitant glycoprotein (GP) IIb/IIIa receptor inhibitors in patients with non-ST-segment elevation acute coronary syndromes who underwent PCI. In Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
Marco Valgimigli et al.
JACC. Cardiovascular interventions, 5(3), 268-277 (2012-03-24)
The authors sought to compare the effect on inhibition of platelet aggregation (IPA) of prasugrel therapy versus tirofiban bolus with or without a post-bolus short drug infusion in ST-segment elevation myocardial infarction (STEMI) patients. The degree and rapidity of IPA
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service